Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen in Spinal Muscular Atrophy
NCT07838779Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of nusinersen in spinal muscular atrophy (SMA). Primary endpoint: Adverse Events at 1 year. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT07838779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838779.